August 8th 2024
The panel discusses treatment considerations for consolidation durvalumab.
The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.
The panel looks at a second patient case study.
The panel discusses management of resectable early-stage non–small cell lung cancer.
The panel discusses the factors that go into selecting patients for adjuvant therapy.
The panel discusses reassessing for respectability after certain treatments.
July 12th 2024
A variety of treatment options in ES NSCLC are explored by key opinion leaders.
The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.
June 25th 2024
Panelists discuss the utilization of testing and multidisciplinary approaches for testing.
Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.
September 13th 2023
Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.
November 9th 2022
The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
November 2nd 2022
Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.
Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.
October 26th 2022
Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.
Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.
October 19th 2022
Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.
Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.
October 17th 2022
The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.
Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.